MIR6892: A Non-Coding RNA Molecule as a Potential Drug Target and Biomarker for Cancer
MIR6892: A Non-Coding RNA Molecule as a Potential Drug Target and Biomarker for Cancer
MicroRNA 6892 (MIR6892) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. MIR6892 is a key regulator of the cell cycle, and its levels have been shown to be altered in a variety of cancer types.
The discovery of MIR6892 as a potential drug target comes from a team of researchers at the University of California, San Diego School of Medicine. The researchers identified MIR6892 as a potential drug target by using a technique called RNA interference, which involves using small interfering RNA (siRNA) to reduce the amount of MIR6892 in the cells.
The researchers found that MIR6892 was highly expressed in various cancer types, including breast, ovarian, and colorectal cancers. They also found that MIR6892 was involved in the regulation of cell cycle progression, and that it was a good candidate for a drug target.
To further investigate the potential of MIR6892 as a drug target, the researchers conducted experiments to see if they could target MIR6892 specifically. They found that an oral drug called rapamycin was able to reduce the amount of MIR6892 in cancer cells, and that this reduced amount of MIR6892 was associated with a decrease in cell proliferation.
The researchers also found that MIR6892 was involved in the regulation of the microtubules, which are important for cell movement and division. They found that MIR6892 was able to alter the structure and stability of these microtubules, which suggests that it may be involved in the regulation of cell division and growth.
In addition to its potential as a drug target, MIR6892 has also been identified as a potential biomarker for cancer. The researchers found that MIR6892 was highly expressed in various cancer types, including breast, ovarian, and colorectal cancers. They also found that the levels of MIR6892 were correlated with the size and stage of the cancer.
The identification of MIR6892 as a potential biomarker for cancer comes from a study by the same researchers who identified it as a potential drug target. The researchers found that MIR6892 was highly expressed in various cancer types, including breast, ovarian, and colorectal cancers, and that its levels were correlated with the size and stage of the cancer.
In conclusion, MIR6892 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. The discovery of MIR6892 comes from a team of researchers at the University of California, San Diego School of Medicine, who used techniques such as RNA interference and microarray analysis to investigate its potential as a drug target and biomarker. Further studies are needed to fully understand the role of MIR6892 in cancer biology and to determine its potential as a drug.
Protein Name: MicroRNA 6892
More Common Targets
MIR6893 | MIR6894 | MIR6895 | MIR7-1 | MIR7-2 | MIR7-3 | MIR7-3HG | MIR708 | MIR7106 | MIR7107 | MIR7108 | MIR7109 | MIR711 | MIR7110 | MIR7111 | MIR7112 | MIR7113 | MIR7114 | MIR7150 | MIR7151 | MIR7152 | MIR7153 | MIR7154 | MIR7155 | MIR7156 | MIR7158 | MIR7159 | MIR7160 | MIR7161 | MIR7162 | MIR718 | MIR720 | MIR744 | MIR7515 | MIR758 | MIR759 | MIR760 | MIR761 | MIR762 | MIR762HG | MIR764 | MIR765 | MIR766 | MIR767 | MIR769 | MIR770 | MIR7702 | MIR7703 | MIR7704 | MIR7705 | MIR7706 | MIR7843 | MIR7844 | MIR7845 | MIR7846 | MIR7847 | MIR7848 | MIR7849 | MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975 | MIR7976 | MIR7977 | MIR802 | MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887
